Managed Account Advisors’s Acorda Therapeutics ACOR Stock Holding History

Managed Account Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$5.65M	Buy	1,412 +25	+2%	+$96.6K	﹤0.01%	1365
2015 Q1	$5.54M	Buy	1,387 +29	+2%	+$133K	﹤0.01%	1388
2014 Q4	$6.66M	Buy	1,358 +128	+10%	+$549K	0.01%	1251
2014 Q3	$5M	Buy	1,230 +180	+17%	+$675K	0.01%	1372
2014 Q2	$4.25M	Sell	1,050 -2	-0.2%	-$8.15K	0.01%	1455
2014 Q1	$4.78M	Buy	1,052 +43	+4%	+$174K	0.01%	1342
2013 Q4	$3.54M	Sell	1,009 -205	-17%	-$799K	﹤0.01%	1468
2013 Q3	$4.98M	Sell	1,214 -74	-6%	-$319K	0.01%	1239
2013 Q2	$5.1M	Buy	+1,288	New	+$5.3M	0.01%	1193

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Managed Account Advisors's ACOR Position: Q2 2015 in Review

Managed Account Advisors increased its Acorda Therapeutics (ACOR) stake by 1.8% in Q2 2015, buying an estimated $96.6K and bringing the position to 1,412 shares worth $5.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1365.

Managed Account Advisors first reported a position in ACOR in Q2 2013 and has held it in 9 quarters since. The position peaked at $6.66M in Q4 2014. 170 funds tracked by Wall St. Rank hold ACOR as of Q2 2015.

Managed Account Advisors held 1,412 shares of Acorda Therapeutics worth $5.65M as of Q2 2015.
Managed Account Advisors bought 25 Acorda Therapeutics shares in Q2 2015, an estimated $96.6K.
Acorda Therapeutics made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #1365 holding.
Managed Account Advisors first reported a position in Acorda Therapeutics in Q2 2013 and has held it in 9 quarters since.
Managed Account Advisors's Acorda Therapeutics position peaked at $6.66M in Q4 2014.
170 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.